Rare and Orphan Diseases - Global Neurology Academy

49-62 of 62

Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
NeuroFrontiers
Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
- Craig M. McDonald, MD
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
NeuroFrontiers
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
- Nancy Kuntz, MD
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
NeuroFrontiers
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
- Nancy Kuntz, MD
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
NeuroFrontiers
Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects
- Maxwell H. Levy, MD
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiers
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiers
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
- Maxwell H. Levy, MD
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
- Gil I. Wolfe MD, FAAN
Challenges in DMD: Understanding the Height Factor
Challenges in DMD: Understanding the Height Factor
NeuroFrontiers
Challenges in DMD: Understanding the Height Factor
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiers
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
NeuroFrontiers
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
NeuroFrontiers
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
- John Brandsema, MD
Continuum of Care: Managing DMD in Pediatric and Adult Patients
Continuum of Care: Managing DMD in Pediatric and Adult Patients
NeuroFrontiers
Continuum of Care: Managing DMD in Pediatric and Adult Patients
- John Brandsema, MD
Advances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety
Advances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety
NeuroFrontiers
Advances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety
- Charles Turck, PharmD, BCPS, BCCCP
- John Brandsema, MD
Uncovering a Potential Biomarker for Myasthenia Gravis
Uncovering a Potential Biomarker for Myasthenia Gravis
NeuroFrontiers
Uncovering a Potential Biomarker for Myasthenia Gravis

Previous
1
2
3
4
Next

4/4